VRDN
Price:
$16.35
Market Cap:
$1.47B
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Industry
Biotechnology
IPO Date
2014-06-18
Stock Exchange
NASDAQ
Ticker
VRDN
According to Viridian Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -4.88. This represents a change of -24.43% compared to the average of -6.46 of the last 4 quarters.
The mean historical PE Ratio of Viridian Therapeutics, Inc. over the last ten years is -4.23. The current -4.88 PE Ratio has changed 11.44% with respect to the historical average. Over the past ten years (40 quarters), VRDN's PE Ratio was at its highest in in the December 2020 quarter at -0.18. The PE Ratio was at its lowest in in the September 2025 quarter at -12.75.
Average
-4.23
Median
-4.19
Minimum
-7.70
Maximum
-0.36
Discovering the peaks and valleys of Viridian Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 461.43%
Maximum Annual PE Ratio = -0.36
Minimum Annual Increase = -86.90%
Minimum Annual PE Ratio = -7.70
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -7.70 | 59.79% |
| 2024 | -4.82 | 17.57% |
| 2023 | -4.10 | -43.18% |
| 2022 | -7.22 | 143.22% |
| 2021 | -2.97 | 461.43% |
| 2020 | -0.53 | 47.13% |
| 2019 | -0.36 | -86.90% |
| 2018 | -2.74 | -63.78% |
| 2017 | -7.57 | 76.99% |
| 2016 | -4.28 | -46.63% |
The current PE Ratio of Viridian Therapeutics, Inc. (VRDN) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-5.54
5-year avg
-5.36
10-year avg
-4.23
Viridian Therapeutics, Inc.’s PE Ratio is greater than uniQure N.V. (-8.28), greater than Structure Therapeutics Inc. (-18.23), greater than Edgewise Therapeutics, Inc. (-21.20), less than Galapagos N.V. (3.36), greater than Ocular Therapeutix, Inc. (-6.90), greater than Vera Therapeutics, Inc. (-6.64), greater than Arcus Biosciences, Inc. (-8.09), greater than Celldex Therapeutics, Inc. (-7.34), greater than ImmunityBio, Inc. (-8.53), greater than Cogent Biosciences, Inc. (-6.30),
| Company | PE Ratio | Market cap |
|---|---|---|
| -8.28 | $1.74B | |
| -18.23 | $2.47B | |
| -21.20 | $3.75B | |
| 3.36 | $1.84B | |
| -6.90 | $1.96B | |
| -6.64 | $2.46B | |
| -8.09 | $2.40B | |
| -7.34 | $2.08B | |
| -8.53 | $7.44B | |
| -6.30 | $5.66B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Viridian Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Viridian Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Viridian Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Viridian Therapeutics, Inc. (VRDN)?
What is the highest PE Ratio for Viridian Therapeutics, Inc. (VRDN)?
What is the 3-year average PE Ratio for Viridian Therapeutics, Inc. (VRDN)?
What is the 5-year average PE Ratio for Viridian Therapeutics, Inc. (VRDN)?
How does the current PE Ratio for Viridian Therapeutics, Inc. (VRDN) compare to its historical average?